Zomagen Biosciences Ltd. has prepared and tested new NLRP3 inflammasome modulators reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, inflammatory disorders, liver diseases, lung diseases, metabolic diseases and neurological disorders.

University of California Oakland and University of Copenhagen scientists have jointly developed calcium/calmodulin-dependent protein kinase type II subunit α (CaMK2A) modulators reported to be useful for the treatment of brain injury, narcolepsy, Angelman syndrome, Down syndrome and stroke.

Research at Prelude Therapeutics Inc. has led to the identification of thaizole-pyrimdiine cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.

A recent Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent describes nitrogen-containing heterocyclic derivatives acting as EGFR (del19 mutant) inhibitors and reported to be useful for the treatment of non-small-cell lung cancer.

Nihon Nohyaku Co. Ltd. has patented azole compounds reported to be useful for the treatment of fungal infections.

Amide compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arthritis, pruritus, asthma, multiple sclerosis, arrhythmia, heart failure and epilepsy, among others.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. scientists have developed kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Histone deacetylase 8 (HDAC8) inhibitors have been reported in a Sookmyung Women’s University patent as potentially useful for the treatment of cancer, neurodegeneration, autoimmune disease, fibrosis and inflammatory disorders.

Work at the Agency For Science Technology & Research Bioprocessing Technology Institute has led to the identification of mitogen-activated protein kinase kinase kinase 14 (MAP3K14; NIK) inhibitors reported to be useful for the treatment of pulmonary fibrosis.